Every Cure is redefining drug discovery by using artificial intelligence to systematically unlock new treatments for rare and undertreated diseases. Founded by Dr. David Fajgenbaum, who survived Castleman disease after repurposing an existing drug, and Grant Mitchell, the nonprofit is on a mission to “systematically identify, validate, and deliver repurposed treatment” to patients in need.
Its proprietary AI platform, MATRIX (Therapeutic Repurposing in eXtended uses), analyzes vast biomedical datasets to evaluate the viability of every possible drug–disease pairing across roughly 4,000 FDA-approved medicines. By surfacing the most promising candidates for repurposing, Every Cure compresses years of trial-and-error into weeks of data-driven prioritization. To date, 87% of MATRIX’s top 100 predictions align with known effective treatments, with more than eight high-impact projects already underway.
Every Cure’s model thrives on collaboration, partnering with technology leaders, pharmaceutical companies, research institutions, patient advocacy groups, and physicians. Guided by a Scientific and Technical Advisory Board, the organization measures success through the accuracy and utility of its AI, the advancement of promising treatments, and the creation of a sustainable ecosystem for repurposing.
Recent breakthroughs include identifying a precision therapy for verbal impairment in individuals with autism by administering folinic acid to bypass blocked folate receptors, restoring speech in some patients. With over $100 million in combined public and philanthropic funding secured, Every Cure is scaling from research to direct patient impact—targeting the launch of five or more high-value projects each year.
By leveraging AI to tap the untapped potential of existing medicines, Every Cure delivers one of the highest returns on investment in healthcare: faster, more affordable access to life-saving treatments, with measurable benefits for patients, healthcare systems, and the field of computational biology itself.
